Brokers Issue Forecasts for TPST FY2028 Earnings

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Equities research analysts at William Blair issued their FY2028 earnings per share (EPS) estimates for Tempest Therapeutics in a note issued to investors on Thursday, March 27th. William Blair analyst M. Phipps forecasts that the company will post earnings per share of ($1.60) for the year. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share.

Other equities analysts have also issued reports about the company. Scotiabank lowered their target price on Tempest Therapeutics from $13.00 to $7.00 and set a “sector outperform” rating for the company in a report on Friday, March 28th. HC Wainwright lowered their price objective on Tempest Therapeutics from $47.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, March 28th.

Tempest Therapeutics Stock Down 3.2 %

TPST opened at $0.71 on Monday. The company’s 50-day moving average price is $0.86 and its 200 day moving average price is $0.97. Tempest Therapeutics has a fifty-two week low of $0.70 and a fifty-two week high of $6.00. The firm has a market cap of $31.19 million, a price-to-earnings ratio of -0.47 and a beta of -1.83.

Tempest Therapeutics (NASDAQ:TPST) last issued its earnings results on Thursday, March 27th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.07). The business had revenue of $0.49 million for the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in shares of Tempest Therapeutics during the third quarter valued at approximately $34,000. Virtu Financial LLC bought a new stake in Tempest Therapeutics during the 4th quarter valued at $36,000. Northern Trust Corp boosted its position in Tempest Therapeutics by 233.2% during the 4th quarter. Northern Trust Corp now owns 67,815 shares of the company’s stock worth $57,000 after acquiring an additional 47,461 shares during the period. Millennium Management LLC bought a new position in shares of Tempest Therapeutics in the fourth quarter worth $158,000. Finally, Geode Capital Management LLC increased its holdings in shares of Tempest Therapeutics by 61.0% during the fourth quarter. Geode Capital Management LLC now owns 354,276 shares of the company’s stock valued at $296,000 after purchasing an additional 134,209 shares during the period. Institutional investors own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.